摘要
目的探讨孟鲁司特钠联合布地奈德混悬液治疗儿童难治性哮喘的效果。方法抽取2020年1月至2021年12月郑州儿童医院收治的儿童难治性哮喘患儿102例进行研究,以双色球法分为对照组与观察组,每组51例。对照组采用布地奈德混悬液治疗,观察组采用孟鲁司特钠联合布地奈德混悬液治疗,比较两组的治疗效果,肺功能[第1秒用力呼气容积占预计值百分比(FEV1%)、用力肺活量(FVC)、FEV1/FVC]、血清炎症因子[白细胞介素-17(IL-17)、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)]及免疫功能[免疫球蛋白A(IgA)、免疫球蛋白G(IgG)、免疫球蛋白M(IgM)]。结果观察组总有效率(98.04%,50/51)高于对照组(84.31%,43/51),P<0.05。治疗前,两组肺功能指标、血清炎症因子指标、免疫功能指标比较差异未见统计学意义(P>0.05);治疗后,观察组FEV1%、FVC、IgA高于对照组,FEV1/FVC、IL-17、CRP、TNF-α及IgG、IgM低于对照组(P<0.05)。结论儿童难治性哮喘予以孟鲁司特钠联合布地奈德混悬液治疗,能更好地改善肺功能、免疫功能,缓解炎症反应,提高临床疗效。
Objective To investigate the effect of montelukast sodium combined with budesonide suspension in the treatment of refractory asthma in children.Methods A total of 102 children with refractory asthma treated in Henan Children’s Hospital from January 2020 to December 2021 were selected for study.A total of 102 children with refractory asthma treated in Zhengzhou Children’s Hospital from January 2020 to December 2021 were selected for the study.And they were divided into control group and observation group by two-color ball method,with 51 cases in each group.The control group was treated with budesonide suspension,and the observation group was treated with montelukast sodium combined with budesonide suspension.The treatment efficacy,lung function assessed by forced expiratory volume in one second percentage(FEV1%)predicted,forced vital capacity(FVC)and FEV1/FVC,serum levels of inflammatory factors including interleukin-17(IL-17),C-reactive protein(CRP)and tumor necrosis factor-α(TNF-α)and immune function assessed by immunoglobulin A(IgA),immunoglobulin G(IgG)and immunoglobulin M(IgM)of the two groups were compared.Results The total effective rate of the observation group(98.04%,50/51)was higher than that of the control group(84.31%,43/51),P<0.05.Before treatment,there was no significant difference between the two groups in lung function index,serum inflammatory factors and immune function indexes(P>0.05).After treatment,the observation group had higher levels of FEV1%,FVC and IgA,but lower levels of FEV1/FVC,IL-17,CRP,TNF-α,IgG and IgM,compared with the control group(P<0.05).Conclusions Montelukast sodium combined with budesonide suspension in the treatment of children with refractory asthma can better improve lung function,immune function,relieve inflammatory response,and improve clinical efficacy.
作者
石聪聪
邰亚辉
王小稳
刘姗姗
杨德彬
Shi Congcong;Tai Yahui;Wang Xiaowen;Liu Shanshan;Yang Debin(Department of Emergency,Children’s Hospital Affiliated to Zhengzhou University,Henan Children’s Hospital,Zhengzhou Children’s Hospital,Zhengzhou 450000,China;Department of Hematology,Children’s Hospital Affiliated to Zhengzhou University,Henan Children’s Hospital,Zhengzhou Children’s Hospital,Zhengzhou 450000,China;Department of Child Health Management Center,Children’s Hospital Affiliated to Zhengzhou University,Henan Children’s Hospital,Zhengzhou Children’s Hospital,Zhengzhou 450000,China)
出处
《中国实用医刊》
2022年第19期104-108,共5页
Chinese Journal of Practical Medicine
基金
2019年度河南省医学科技攻关计划联合共建项目(LHGJ20190913)。
关键词
哮喘
布地奈德混悬液
孟鲁司特钠
肺功能
炎症因子
免疫功能
Asthma
Pulmicoride
Montelukast sodium
Pulmonary function
Inflammatory factors
Immune function
